When Wayne mentioned the immunotherapies partnership he seemed to allude to potentially a majority sale.
He said we'll have an equity stake which sounds to me like less than a controlling stake.
Happy with that. Drug development is just too expensive and lead times are too long. So uncertain as well. Iterating new adapt products sounds like a much smarter play.
Wonder how Fraser is feeling about it. Could potentially end up working to make money for big pharma again.
Ann: AGM Live Stream Webinar Registration Open, page-107
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.85 |
Change
-0.150(0.79%) |
Mkt cap ! $362.3M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.20 | $18.72 | $106.0K | 5.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 379 | $18.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.85 | 1753 | 1 |
View Market Depth
| Last trade - 15.57pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.84 |
Change
-0.150 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $18.94 | $19.01 | $18.84 | 315 | ||
| Last updated 15.52pm 27/05/2024 ? | |||||
| AVR (ASX) Chart |